← Leaderboards
Paytsar Topchyan
Versiti Blood Health, Inc.
$200,182
Attributed
$200,182
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $52.7K · FY2020–23$100K$75K$50K$25K$0
'20
'21
'22
'23
Funding mix
By agency
NIH$200,182 · 1
By mechanism
F30$200,182 · 1
Top collaborators
No co-investigators on record.
Most similar at Versiti Blood Health, Inc.
Same institution · by research overlap
- Renren Wen$8,580,385
Others in their field
Other Emerging Leaders on “Adoptive Transfer”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
- Bronwen Shaw · Medical College Of Wisconsin$10,707,191
- Colin Masters · University Of Melbourne$10,651,748
- Akila Subramaniam · University Of Alabama At Birmingham$6,547,544
- Sarah Emily Snider · Beam Diagnostics, Inc.$5,670,978
- Pradeep Natarajan · Massachusetts General Hospital$4,959,712
Research focus
Adoptive TransferAntitumor ResponseAntiviral ImmunityBindingCancer CellCancer ImmunotherapyCd4 Positive T LymphocytesCd8-Positive T-LymphocytesCell MaintenanceCell PhysiologyCellsCell SurvivalChromatinChronicChronic InfectionCytokineCytotoxicityEffector CellExhaustExhaustionExhibitsExperimental StudyFellowshipAdoptive Cell Transfers
Grant awards (4)
Reprogramming tumor-reactive CD8 T cells by targeting the IL-21-BATF pathway to treat melanoma$52,694
F30 · FY2023 · CA · contact PI
Reprogramming tumor-reactive CD8 T cells by targeting the IL-21-BATF pathway to treat melanoma$51,752
F30 · FY2022 · CA · contact PI
Reprogramming tumor-reactive CD8 T cells by targeting the IL-21-BATF pathway to treat melanoma$48,126
F30 · FY2021 · CA · contact PI
Reprogramming tumor-reactive CD8 T cells by targeting the IL-21-BATF pathway to treat melanoma$47,610
F30 · FY2020 · CA · contact PI